独角兽企业如何判断IPO是正确的战略选择
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.
Congratulations on personalizing your experience.
Email is verified. Thank you!
The relative strength of a dividend stock indicates whether the stock is uptrending or not. The major determining factor in this rating is whether the stock is trading close to its 52-week-high.
If a stock’s yield is above or near the market average then it will be rated higher within this parameter. High dividend yields (usually over 10%) should be considered extremely risky, while low dividend yields (1% or less) are simply not very beneficial to long-term investors.
A stock’s dividend reliability is determined by a healthy payout ratio that is higher than other stocks. A company that pays out close to half its earnings as dividends and retains the other half of 独角兽企业如何判断IPO是正确的战略选择 earnings has ample room to grow its business and pay out more dividends in the future.
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. If a stock is valued 独角兽企业如何判断IPO是正确的战略选择 near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
A stock’s Earnings Growth rating evaluates a company’s expected EPS for the current 独角兽企业如何判断IPO是正确的战略选择 financial year and compares it to next financial year’s expected EPS . Stocks with single-digit growth estimates will have a higher rating than others, as our research has shown that well-established dividend-paying 独角兽企业如何判断IPO是正确的战略选择 companies have modest earnings growth estimates.
Renaissance IPO ETF
Vitals
3 Yr Avg Return
5 Yr Avg Return
Holdings in Top 10
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 0.60%
SALES FEES
Deferred Load N/A
TRADING FEES
Redemption Fee N/A
Min Investment
Fund Classification
Exchange Traded Fund
IPO - Profile
Distributions
- YTD Total Return -46.6%
- 3 Yr Annualized Total Return 1.7%
- 5 Yr Annualized Total Return 4.5%
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.30%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Quarterly
Fund Details
Fund Description
The fund seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the index. It normally invests at least 80% of its total assets in securities that comprise the index. The index is a portfolio of companies that have recently completed an initial public offering ("IPO") and are listed on a U.S. exchange. The fund is non-diversified.
独角兽企业如何判断IPO是正确的战略选择
独角兽企业如何判断IPO是正确的战略选择Grand Farm Inc. Filed, US Offering, Removed, Nasdaq: GFRM
Produces milled rice to sell under the "Grand Farm" brand to distributors.
Latest Trade: ()
First Day Return:
Return from IPO:
| IPO Data | |
|---|---|
| IPO File Date | 05/13/2011 |
| Offer Price | |
| Price Range $0.00 - $0.00 | |
| Offer Shares (mm) | 0.0 |
| Deal Size ($mm) | $30 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | |
| Offer Price | |
| Price Range $0.00 - $0.00 | |
| Offer Shares (mm) | 0.0 |
| Deal Size ($mm) | $30 | 独角兽企业如何判断IPO是正确的战略选择 独角兽企业如何判断IPO是正确的战略选择
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
AKRO News
US IPO Week Ahead: Just 1 biotech is on the calendar in a slow week for the IPO market
After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead. NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company’s target indication represents a multi-billion-dollar market with no FDA-approved therapy; consequently, there are . read more
NASHville: 89bio is the latest biotech IPO targeting liver disease NASH
Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH biotech, Cirius Therapeutics (CSTX), is in the IPO pipeline, but before this year, the last biotech IPO targeting NASH came in. read more
June's flood of biotech IPOs continues with these 4 deals
June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week. Recent biotech IPOs have mostly underperformed, though 2 are up +100% . read more
US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public
Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week with losses. The stock closed Friday at $37.22, down 3.3% from 独角兽企业如何判断IPO是正确的战略选择 the opening trade. With millions of users. read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
The IPO Decision
The IPO Decision is an exciting new book that clarifies how 独角兽企业如何判断IPO是正确的战略选择 独角兽企业如何判断IPO是正确的战略选择 the initial public offering (IPO) process actually works. It separates fact from fiction and imposes a logical structure on the most up-to-date IPO-related research. All major topics pertaining to the going-public process are included: IPO timing, the financial, strategic, and corporate governance benefits and costs of public ownership, 独角兽企业如何判断IPO是正确的战略选择 corporate restructuring, valuation, the role of the investment bank in the primary and secondary markets, 独角兽企业如何判断IPO是正确的战略选择 the optimality of IPO mechanisms (book-building vs. auctions), analyst coverage, and the long-run performance of IPOs.
The IPO Decision is an exciting new book that clarifies how the initial public offering (IPO) process actually works. It separates fact from fiction and imposes a logical structure on the most up-to-date IPO-related research. All major topics pertaining to the going-public process are included: IPO timing, the financial, strategic, and corporate governance benefits and costs of public ownership, corporate restructuring, valuation, the role of the investment bank in the primary and secondary markets, the optimality of IPO mechanisms (book-building vs. auctions), analyst coverage, and the long-run performance of IPOs.
IPOs garnered unprecedented positive attention in the 1990s for their spectacular returns and central role in entrepreneurial activity. Subsequent revelations of unscrupulous IPO allocation and promotion practices cast a less favorable shadow. The latest significant event in the IPO market is Google’s unconventional use of an auction for its offering. Public discussion and debate about these developments has often taken place in an information vacuum, leading to misunderstandings and false conclusions.
Unparalleled in its scope, The IPO Decision presents the findings from theoretical and empirical research in a rigorous yet accessible manner. In doing so, it develops the intellectual foundation necessary for a constructive dialogue about reforming the IPO process. Scholars, students and industry professionals interested in the economics of IPOs will find this volume a comprehensive and engaging addition 独角兽企业如何判断IPO是正确的战略选择 to their library.
‘Because of its scope and detail, The IPO Decision would be a useful addition to an academic library serving a finance program or that has a financial services library. Public librarians might consider this book if they have a large constituency of sizable private businesses of finance students.’
– Janet Hartman, Research Librarian, William Blair & Co, Chicago, Business Information Alert
‘This volume certainly belongs in undergraduate libraries. Faculty who teach courses in the economics of finance can use the book as a reference and as a guide for students working on papers on the economics of initial public offerings (IPOs). Draho summarizes the extant literature on all aspects of the subject. For example, a student interested in the valuation process underlying initial public offerings receives a well-written overview of the approaches used, including both discounted cash flows and real option analysis. Students are also guided to the relevant literature on the subject. . . a useful resource for beginning research on this topic. Highly recommended.’
– W.S. Curran, Choice
‘Jason Draho’s The IPO Decision is a clear, well organized, and especially well researched book on the IPO environment, process, and stock price results.’
– Roger G. Ibbotson, Yale University and Chairman, Ibbotson Associates, Inc., US
‘Even more important in the post-Internet bubble world, The IPO Decision by Jason Draho provides a critical, in-depth and practical perspective on the crucial terms and factors that influence the IPO process. From the company that plans to go public (or its professional advisor) to the buy side or sell side investment banker – the book provides a roadmap for all professionals associated with the IPO process.’
– Ross Barrett, President and Co-Founder, VC 独角兽企业如何判断IPO是正确的战略选择 Experts, Inc., New York, US
‘This book provides a comprehensive description and analysis of why and how firms float on the Stock Market. It reviews and takes forward current research on a range of issues concerning the price of shares at flotation and after.’
– Jonathan Michie, Birkbeck College, University of London, UK
Contents: Preface 1. Introduction 2. IPO Timing and Information 3. Financing Options and Costs 4. Strategic Behavior 5. Control, Monitoring and Governance 6. The External Market: An International Comparison 7. Corporate Restructuring 8. Valuation 9. Preparing for the IPO 10. IPO Mechanisms: Allocations and Pricing 11. The IPO Aftermarket 12. Post-IFO Financing 13. Long-run Performance 14. Final Thoughts References Index